NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Humacyte and certain of its officers an ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible.Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair.Also Read: Delay Hits Humacyte’s Bioengineered Hum ...

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/humacyte-inc-lawsuit-su ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC filings, Ayabudge LLC, an entity controlled by Board member Brady W. Dougan, who is married to CEO and President Laura Niklason, disposed of 1.5 million shares over three days in November, netting approximately $6.6 million. The sales, which were treated as indirectly benefiting Dr. Niklason, came as Humacyte navi ...

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/humacyte-inc-laws ...

NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=117271&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=117013&from=3 CLASS PERIOD: May 10, 2024 to O ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 17, 2025 [2][4]. Group 1: Allegations Against Humacyte - The complaint alleges that Humacyte and its executives made false or misleading statements and failed to disclose significant issues regarding their manufacturing practices and FDA approval process [4]. - Specific allegations include non-compliance with good manufacturing practices at the Durham, North Carolina facility, leading to delays in the FDA's review of the Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) [4]. - The complaint suggests that these issues posed a substantial risk to the FDA approval of ATEV for vascular trauma, rendering the company's positive statements materially misleading [4]. Group 2: Stock Price Impact - Following a press release on August 9, 2024, regarding the FDA's need for additional time to review the BLA, Humacyte's stock price fell by $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [5]. - On October 17, 2024, the FDA released a Form 483 detailing violations at Humacyte's facility, resulting in a further decline of $0.95, or 16.35%, with the stock closing at $4.86 per share on the same day [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 between May 10, 2024, and October 17, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for January 17, 2025 [2][7].

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=116392&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

Core Viewpoint - A class action securities lawsuit has been filed against Humacyte, Inc. due to alleged securities fraud affecting investors between May 10, 2024, and October 17, 2024 [1] Group 1: Allegations - The lawsuit claims that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, including quality assurance and microbial testing [2] - It is alleged that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies [2] - There is a substantial risk to the FDA approval of Humacyte's acellular tissue engineered vessel for vascular trauma as a result of these issues [2] - The defendants' positive statements regarding the company's business and prospects were misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 17, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]